Wednesday, February 20, 2019
Trovagene Inc. (TROV)
Room for improvement in early prostate cancer data.
TrovaGene Inc is a
US-based life science company which focuses on the development and
commercialization of a proprietary molecular genetic detection technology for
use in pharmaceutical development, clinical research and medical testing across
a variety of clinical disciplines, including oncology and virology.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
RATING: OUTPERFORM
- ASCO GU Data
Presentations. The company presented early unfavorable data from the Phase 2 Study of Onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer at the Genitourinary Cancers Symposium on February 14. The clinical benefit in patients was determined by the prostate-specific antigen (PSA) level and reduction was observed only transiently. - Adjusted Dosing Schedule. We believe the adjustment in dosing schedule and levels is not uncommon in early stages of drug development, The company intends to open a second arm, reducing the dose cycle to 14 days from 21 days t…
GO TO FULL REPORT
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
